Search company, investor...

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Seed VC | Alive

Total Raised


Last Raised

$350K | 15 yrs ago

About Abeome

Abeome is a biotechnology firm dedicated to leveraging its technology that aims to enhance the speed, efficiency and stability of developing and producing monoclonal antibodies.

Abeome Headquarters Location

111 Riverbend Road Georgia Biobusiness Center

Athens, Georgia, 30605,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Abeome

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Abeome is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Abeome Patents

Abeome has filed 2 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Immune system
  • Monoclonal antibodies
patents chart

Application Date

Grant Date


Related Topics



Clusters of differentiation, Interleukins, Monoclonal antibodies, Immunology, Immune system


Application Date


Grant Date


Related Topics

Clusters of differentiation, Interleukins, Monoclonal antibodies, Immunology, Immune system



Latest Abeome News

Newly Formed Lanier Biotherapeutics Enters into License Agreement with Alloy Therapeutics

Oct 5, 2021

Suwanee, Georgia, UNITED STATES BOGART, Ga., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Lanier Biotherapeutics Inc., (“Lanier” or the “Company”), a developer of first-in-class antibodies targeting retina, dermatology, and Type 2 Inflammatory specialty diseases, today announced that it has entered into a license agreement (the “Agreement”) with Alloy Therapeutics (“Alloy”), a privately held drug discovery company. Alloy will acquire the AbeoMouse™ and Direct Selection of Hybridomas (DiSH™) antibody discovery technologies, which were originally developed by Abeome Corporation, Inc. (“Abeome”), one of Lanier’s two predecessor companies. Upon closing of the Agreement, Alloy will license to Lanier certain rights to AbeoMouse™ and Alloy’s ATX-Gx™ platform of proprietary transgenic mouse strains. “We are pleased to enter into this mutually beneficial Agreement, which provides both companies with access to enabling antibody discovery technologies while augmenting our development pipeline and further strengthening our balance sheet,” said Kirby Alton, Lanier’s Chairman. Lanier was recently formed by combining the businesses of Abeome and Biophtha Inc., with bridge funding from investors, including founders Kirby Alton, PhD, former Senior Vice President of Development at Amgen; and Daniel White, MBA, former CEO of Clearside Biomedical. Messrs. Alton and White are joined by Lanier’s other two founders, Martin Simonetti, MS, MBA and Chris McLeod, MS, to form Lanier’s experienced leadership team: President, CEO & Director, Daniel White, is an accomplished entrepreneur and visionary in the biotech and pharmaceutical space. As the founder and CEO of Clearside Biomedical, he led the company from early private financing through its initial public offering and brings a wealth of biomedical development and successful fundraising experience. Chairman, Kirby Alton, reprises his role of Chairman of Abeome, and brings deep product development expertise gained as one of Amgen’s original scientists. Director, Martin Simonetti, has significant Amgen and Genentech experience; an immense track record of leadership and growth across several biotechnology enterprises; and has led successful financings in both private and capital markets. Director, Chris McLeod, is an experienced biotechnology executive with vast expertise in growth companies and strategic collaborations. He is a former Executive Vice President of CuraGen and President of 454 Life Sciences; and is the current managing partner of Elm Street Ventures. Lanier is developing a portfolio of 11 first-in-class therapeutic antibodies for specialty disease across four major verticals: Multi-functional Retina, Type 2 Inflammation, Dermatology, and ImmunoOncology. “With a robust portfolio of 11 first-in-class, proprietary therapeutic antibodies, we are eager to progress toward the clinic with our two lead candidates: one targeting retinal disease using our multifunction anti VEGF inhibitor and the second using the most advanced and proprietary anti IL25 to treat Type 2 Inflammatory diseases,” said Daniel White, President and CEO of Lanier. “Lanier has initiated a fund raise to launch these two programs that hold promise for improving treatment to provide a better life for patients.” Multi-functional Retina Lanier’s LNR 653.1 is a proprietary bifunctional antibody being developed for the treatment of retinal neovascularization diseases (wet age-related macular degeneration, diabetic macular edema and retinal vein occlusion. LNR 653.1 is designed to combine the anti-vascular endothelial growth factor (VEGF) effect of aflibercept (marketed as Eylea by Regeneron) with the anti-inflammatory and anti-apoptotic effects similar to that of secukinumab (marketed as Cosentyx by Novartis). Preclinical data suggest that LNR 653.1 is safe, with efficacy similar or superior to aflibercept. Lanier is currently conducting pre-formulation experiments and non-clinical functional testing, with plans to initiate investigational new drug (“IND”)-enabling studies of LNR 653.1 in 2022. Type 2 Inflammation LNR 125.38 is a monoclonal antibody that inhibits the upstream cytokine IL-25. By reducing, or even eliminating the effects of downstream allergic and antiviral cytokines, LNR 125.38 targets Type 2 Inflammation, which is implicated in different atopic, allergic and inflammatory diseases. Lanier is prioritizing the development of LNR 125.38 across a broad range of potential treatments of moderate to severe asthma that is classified as either high or low eosinophil challenge by allergy or rhinovirus; chronic sinusitis with nasal polyps; and eosinophil esophagitis and gastritis. Preclinical data have demonstrated that LNR 125.38 significantly reduces Type 2 (downstream) cytokines and inflammatory cells in allergic mouse and rhinovirus-induced asthma exacerbations. Lanier is currently conducting pre-formulation experiments and non-clinical functional testing, with plans to initiate IND-enabling studies of LNR 125.38 in the second half of 2022. Dermatology Lanier is developing LNR 653.1 for the treatment of psoriasis, where functional testing has demonstrated potency and efficacy comparable to secukinumab and ixekizumab (marketed as Taltz by Eli Lilly). The Company is also developing LNR 125.38 for the treatment of chronic urticaria and atopic dermatitis. ImmunoOncology MT-6402 is an engineered toxin body manufactured by Molecular Templates, Inc., which contains a PDL-1 inhibitor previously licensed by it from Lanier’s extensive library of proprietary checkpoint inhibitors. In July, Molecular Templates dosed the first subject in a Phase 1 study evaluating MT-6402 in patients with PD-L1-positive solid tumors and expects to provide an update on the study by the end of this year. About Alloy Therapeutics Alloy Therapeutics is a biotechnology ecosystem company empowering the global scientific community to make better medicines together. Through a community of partners, Alloy democratizes access to tools, technologies, services, and company creation capabilities that are foundational for discovering and developing therapeutic biologics. The company facilitates affordable, non-exclusive access to the entire drug discovery community from academic scientists, small and medium biotech, to the largest biopharma. Alloy’s lead offering, the ATX-Gx™ platform, is a human therapeutic antibody discovery platform consisting of a growing suite of proprietary transgenic mice strains. Founded in 2017 and privately funded by visionary investors, Alloy is headquartered in Boston, MA with European labs in Cambridge, UK. As a reflection of Alloy’s relentless commitment to the scientific community, Alloy reinvests 100% of its revenue in innovation and access to innovation. About AbeoMouse™ AbeoMouse™ is a novel transgenic antibody discovery platform that generates mature B-cells with high surface immunoglobulin (Ig) expression, allowing for the direct selection and cloning of antigen-specific B-cells. AbeoMouse™ over-expresses immunoglobulin co-receptors alpha (Ig- / CD79a), beta (Ig- / CD79b) and interleukin 6 (IL6) genes, such that immunized animals produce a 45-fold increase in surface Ig positive antibody secreting cells and an accelerated immune response. About DiSH™ DiSH™ technology enables the rapid selection and cloning of antigen-specific hybridomas. Using fluorescence activated cell sorting (FACS) or magnetic separation, desired hybridomas can be labelled and subsequently isolated from among a pool of hundreds of thousands of cells, in a matter of hours. About Lanier Biotherapeutics Lanier Biotherapeutics was founded by combining the businesses of Biophtha and Abeome, to further develop an existing first-in-class biologics portfolio for specialty disease, with the ultimate goal of improving the way we survive, age, and live. Lanier targets four major verticals: Multi-functional Retina, Type 2 Inflammation, Dermatology, and ImmunoOncology. Lanier’s lead developments programs include LNR 653.1, a fully humanized anti-VEGF / IL-17A multifunctional antibody for the treatment of retinal neovascularization diseases and LNR 125.36, a fully humanized anti-IL-25 monoclonal antibody for the treatment of Type 2 Inflammatory diseases. For more information, please visit . Contact:

  • When was Abeome founded?

    Abeome was founded in 2000.

  • Where is Abeome's headquarters?

    Abeome's headquarters is located at 111 Riverbend Road, Athens.

  • What is Abeome's latest funding round?

    Abeome's latest funding round is Seed VC.

  • How much did Abeome raise?

    Abeome raised a total of $350K.

  • Who are the investors of Abeome?

    Investors of Abeome include Advanced Technology Development Center, Georgia Venture Partners and Georgia BioBusiness Center.

  • Who are Abeome's competitors?

    Competitors of Abeome include Marinomed Biotech, Biosceptre International, Onyx Pharmaceuticals, Vaccinogen, Zyngenia and 12 more.

You May Also Like

Alethia BioTherapeutics

Alethia BioTherapeutics is a biotechnology company that develops monoclonal antibody therapeutics to clinically relevant targets identified using its STAR discovery technology.


Spaltudaq Corporation, a privately-held biotechnology company based in Seattle, is focused on developing therapeutic antibodies for the treatment of inflammation, infectious disease and cancer. Our technology harnesses the power of the human immune system to identify tumor-specific or pathogen-specific monoclonal antibodies from human tissue samples.

Aliva Biopharmaceuticals

Aliva Biopharmaceuticals is a company that received a SBIR Phase I grant for a project entitled: Humanized Mouse Ig system employing BAC. Their research project aims to introduce the entire human immunoglobulin locus into the mouse in order to enable the subsequent production of completely humanized monoclonal antibodies from hybridomas. Monoclonal antibodies against cell surface proteins are currently being used for a variety of clinical indications, including cancer and autoimmunity. Their binding avidity and specificity make them one of the most important modes of therapy for the treatment of a variety of diseases where specific targeting is required. The current technology is based on a system where only 80% of the immunoglobulin locus has been humanized. Replacement of the remaining mouse genes with the human ones will improve the quality and diversity of the antibodies produced and as such, will be an important contribution to this important therapeutic modality.


GlycoMar Limited is the European centre for marine biotechnology and glycobiology. GlycoMar is an Research & Development and development company pursuing untapped biological and chemical diversity to identify drug candidates from marine organisms.

Institute of Forest Biotechnology

The institute works for societal, ecological, and economic benefits from the appropriate uses of biotechnology in forestry worldwide. The company's cornerstone programs are Heritage Trees, Ecological Ramifications, Societal Issues and Outreach.

Kenta Biotech

Kenta Biotech is focusing on the discovery and development of fully human monoclonal antibodies for the life-saving treatment of patients with serious infectious diseases.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.